Research and Markets: Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c23018) has announced the addition of Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact to their offering Phosphodiesterases (PDEs) are the enzyme enzyme, biological catalyst. The term enzyme comes from zymosis, the Greek word for fermentation, a process accomplished by yeast cells and long known to the brewing industry, which occupied the attention of many 19th-century chemists. superfamily superfamily /su·per·fam·i·ly/ (soo´per-fam?i-le) 1. a taxonomic category between an order and a family. 2. of drug targets that underlie PDE PDE Pennsylvania Department of Education PDE Plug-In Development Environment PDE Partial Differential Equation PDE Phosphodiesterases PDE Personal Digital Entertainment PDE Pulse Detonation Engine PDE Product Data Exchange PDE Present-Day English inhibitor development. As such, PDEs are emerging as a promising class of drug targets. The most significant recent development for PDE inhibitors was the approval of the first selective PDE inhibitor inhibitor /in·hib·i·tor/ (in-hib´i-tor) 1. any substance that interferes with a chemical reaction, growth, or other biologic activity. 2. , Viagra(R), in 1998. Two further high profile approvals of new PDE inhibitors, which also address erectile dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. , have taken place. As industry awaits approval of two PDE inhibitors for new disease indications, the 'Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact' report highlights the broad applicability of PDEs, providing the reader with useful background information about current pipeline and market developments. The central focus of the 'Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact' report is an assessment of the therapeutic and market potential of phosphodiesterase inhibitors phos·pho·di·es·ter·ase inhibitor n. Any of a class of drugs that suppress the enzyme phosphodiesterase, increasing the production of cyclic GMP, which facilitates vasodilation, causing erection in males. . A systematic review of PDEs is presented, including review of the 11 known phosphodiesterase phosphodiesterase /phos·pho·di·es·ter·ase/ (-di-es´ter-as) any of a group of enzymes that catalyze the hydrolytic cleavage of an ester linkage in a phosphoric acid compound containing two such ester linkages. families. Pharma pipelines and disease indications addressed by PDE inhibitors aid review of their therapeutic potential. A market assessment reviews the disease markets addressed by current PDE inhibitors e.g. asthma, COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) and erectile dysfunction markets. This report will allow you to: - Determine what is new in PDE inhibitor development by review of clinical developments in current pharmaceutical pipelines. - Assess the therapeutic potential of PDE inhibitors by identification of the major disease indications addressed by approved PDE inhibitors and those in clinical development. - Assess the market potential of PDE inhibitors from maps of the current market landscape, an evaluation of the success of approved PDE inhibitors, and consideration of future market projections relevant to PDE inhibitors. - Get an up-to-date perspective on PDE inhibitor targets with a systematic review of each PDE family. - Identify the key technological platforms currently utilized in PDE-targeted drug discovery. - Look inside 20 companies involved in PDE-related drug discovery, including their product pipelines, financial standing, partnerships & alliances, and more. - Obtain a current industry snapshot (1) A saved copy of memory including the contents of all memory bytes, hardware registers and status indicators. It is periodically taken in order to restore the system in the event of failure. (2) A saved copy of a file before it is updated. of PDE-related drug discovery from a short survey conducted in parallel with the writing of this report. - Gain insight into current challenges in PDE-related drug discovery through in-depth interviews with five industry experts. This report answers the following questions: - Who is currently developing PDE inhibitors? - What are the disease indications addressed by PDE inhibitors in advanced clinical development? - How are PDE inhibitors addressing unmet un·met adj. Not satisfied or fulfilled: unmet demands. medical needs? - What are the competitive advantages of second-generation PDE inhibitors? - Why is a PDE program attractive in pharmaceutical R&D? - What are the relative merits of approved PDE inhibitors? - Which PDE targets are considered to have the most therapeutic and commercial potential? - Which areas of PDE inhibitor development have high priority research needs? - What are the future prospects for PDE inhibitors? Companies profiled: - ALTANA Pharma AG - Bayer HealthCare - Celgene Corp. - CrystalGenomics, Inc - deCODE genetics deCODE genetics, Inc. (Íslensk erfðagreining in Icelandic) NASDAQ: DCGN is a biopharmaceutical company based in Reykjavík, Iceland. The company was founded in 1996 to identify human genes associated with common diseases using population studies, and apply the - elbion AG - GlaxoSmithKline, plc - Glenmark Pharmaceuticals Ltd - ICOS Corp. - Inflazyme Pharmaceuticals Ltd - Memory Pharmaceuticals Corp. - Neuro3d - Nissan Chemicals Industries Ltd - Otsuka America Pharmaceutical, Inc - Pfizer, Inc - Plexxikon, Inc - Sequenom, Inc - Schering-Plough Corp. - Wyeth - Vivus, Inc For more information visit http://www.researchandmarkets.com/reports/c23018 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion